Malignant Mesothelioma vs. Reactive Mesothelial Proliferations: Immunohistochemical Profile
L. Moretti, A. García, S. Nieto, B. Elsner, A. Avagnina, V. Denninghoff
Journal of Advances in Medicine and Medical Research · pp. 95–103 · Published 14 Sep 2013
10.9734/BJMMR/2014/3180Abstract
Aims: To examine the distribution of immunohistochemical markers GLUT-1, EMA (membrane epithelial antigen) and Ki-67 in benign and malignant mesothelial lesions. Thus, the sensitivity, specificity, positive and negative predictive value of these markers, used alone or in conjunction, was established. Study Design: Observational, retro-prospective and non-randomized study. Place and Duration of Study: Department of Pathology, Center for Medical Education and Clinical Research "Norberto Quirno" (CEMIC), between 2004 and 2011. Methodology: A total of 53 cases diagnosed as mesothelioma (n=15) or reactive mesothelial hyperplasia (n=38) were selected. Routine techniques using hematoxylin-eosin and immunostaining with EMA, GLUT-1, and Mib-1 were performed. Results: Mesotheliomas cohort was immunoreactive for GLUT-1 in 11/15 (73%) cases, and for EMA in 13/15 (87%) cases. The group of reactive lesions was positive for GLUT-1 in 2/38 cases (5%), and positive for EMA in 7/38 (18%) cases. The median proliferation rate was 1% in benign lesions and 3% in mesotheliomas. The sensitivity and specificity for EMA was 87% and 82% respectively, with a positive predictive value of 65% and a negative predictive value of 94%. The sensitivity and specificity for GLUT-1 was 73% and 95% respectively, with a positive predictive value of 85% and a negative predictive value of 90%. Conclusion: EMA and GLUT-1 are sensitive and specific markers that express more frequently in mesothelioma than in benign mesothelial lesions with higher specificity in the case of GLUT-1 for the detection of malignant proliferations. In a mesothelial proliferation without invasion criteria, EMA and GLUT-1, including histopathology, may be sensitive and specific markers to define malignancy. Thus, a morphologically doubtful mesothelial proliferation with positive staining (diffuse and intense), for these antibodies could be a mesothelioma. However, the evidence of underlying tissue infiltration by mesothelial cells currently remains the gold standard for diagnosis of mesothelioma. Both markers should be included in the immunohistochemical panel to distinguish benign from malignant mesothelial lesions.
References (10)
- 1 Factors Predictive of Survival Among 337 Patients With Mesothelioma Treated Between 1984 and 1994 by the Cancer and Leukemia Group B [DOI]
- 2 Differential subcellular distribution of glucose transporters GLUT1–6 and GLUT9 in human cancer: Ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues [DOI]
- 3 The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet‐derived growth factor‐receptor, P‐glycoprotein and Bcl‐2 [DOI]
- 4 The Diagnostic Utility ofp16FISH and GLUT-1 Immunohistochemical Analysis in Mesothelial Proliferations [DOI]
- 5 Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports [DOI]
- 6 PTEN expression is a strong predictor of survival in mesothelioma patients☆ [DOI]
- 7 IMP3 and GLUT-1 Immunohistochemistry for Distinguishing Benign From Malignant Mesothelial Proliferations [DOI]
- 8 The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses [DOI]
- 9 Textbook of Lung Cancer
- 10 Assessment of cell cycle state may facilitate the histopathological diagnosis of malignant mesothelioma [DOI]
Cited by 6
Kai Zhang, Hongbing Deng, Philip T. Cagle · Handbook of Practical Immunohistochemistry · 2015
Kai Zhang, Hongbin Deng, Philip T. Cagle · Archives of Pathology & Laboratory Medicine · 2014
Hongbing Deng, Kai Zhang · Handbook of Practical Immunohistochemistry · 2022
Showing 3 of 6 known citations — external sources report more than can currently be individually listed.
Related research
- Common Approaches of Cytochrome P450 (CYP) Induction Assays — shares topic coverage
- Roles and Rules of Some Regulatory Agencies around the World during COVID-19 Pandemic — shares topic coverage
- Current Updates on in vitro Dissolution Testing for Immediate Release Oral Dosage Forms — shares topic coverage
- Sarcomatoid Carcinoma (Carcinosarcoma) of the Prostate Gland: A Review of the Literature — shares topic coverage
- Primary Synovial Sarcoma of the Prostate Gland: A Review of the Literature — shares topic coverage
Article metrics
Real usage data collected on this platform.
38
Page views
0
PDF downloads
4
Outbound clicks
6
Citations
Views over time
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
Traffic sources
Referring site, by host.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.